A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Summary

The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM. This study is seeking participants who: Are 18 years of age or older or minimum legal adult age as defined per local regulation, whichever is greater Have active DM or active PM. Are receiving a stable dose of 1 corticosteroid taken by mouth and/or 1 traditional immunosuppressant.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Myositis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

September 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites